[{"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher C. Gibson Ph.D.", "age": 41, "title": "Co-Founder, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 806716, "exercisedValue": 2177540, "unexercisedValue": 222044}, {"maxAge": 1, "name": "Dr. Blake C. Borgeson Ph.D.", "age": 42, "title": "Co-Founder & Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David J. Mauro M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 674737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben R. Taylor", "age": 47, "title": "CFO & President of Recursion UK", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen  Rushton M.B.A.", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kevin  Leggat", "title": "Vice President of Finance & Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Mabey M.S.", "age": 41, "title": "Chief Technology Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Hallett Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jared  Allenbach", "title": "Senior Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  Hatfield", "title": "Chief Legal Officer & General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.76, "open": 6.89, "dayLow": 6.71, "dayHigh": 7.485, "regularMarketPreviousClose": 6.76, "regularMarketOpen": 6.89, "regularMarketDayLow": 6.71, "regularMarketDayHigh": 7.485, "beta": 0.802, "forwardPE": -4.3667593, "volume": 16420911, "regularMarketVolume": 16420911, "averageVolume": 10192191, "averageVolume10days": 16211180, "averageDailyVolume10Day": 16211180, "bid": 7.16, "ask": 7.25, "bidSize": 1400, "askSize": 1400, "marketCap": 2817105408, "fiftyTwoWeekLow": 5.6, "fiftyTwoWeekHigh": 15.74, "priceToSalesTrailing12Months": 43.217743, "fiftyDayAverage": 6.8074, "twoHundredDayAverage": 7.669525, "currency": "USD", "enterpriseValue": 1602004480, "floatShares": 252423384, "sharesOutstanding": 383724000, "sharesShort": 67097533, "sharesShortPriorMonth": 64573303, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1717, "heldPercentInsiders": 0.03502, "heldPercentInstitutions": 0.68583, "shortRatio": 4.72, "shortPercentOfFloat": 0.1872, "impliedSharesOutstanding": 390721984, "bookValue": 1.833, "priceToBook": 3.9334426, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -377751008, "trailingEps": -1.54, "forwardEps": -1.73, "enterpriseToRevenue": 24.577, "enterpriseToEbitda": -4.399, "52WeekChange": -0.39153916, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RXRX", "underlyingSymbol": "RXRX", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1618579800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "b61b6c65-adf4-3158-aa09-6b9439d85de8", "messageBoardId": "finmb_261401243", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.21, "targetHighPrice": 12.0, "targetLowPrice": 6.0, "targetMeanPrice": 9.85714, "targetMedianPrice": 10.0, "recommendationMean": 2.625, "recommendationKey": "hold", "numberOfAnalystOpinions": 7, "totalCash": 427647008, "totalCashPerShare": 1.491, "ebitda": -364150016, "totalDebt": 90625000, "quickRatio": 3.948, "currentRatio": 4.355, "totalRevenue": 65184000, "debtToEquity": 17.276, "revenuePerShare": 0.265, "returnOnAssets": -0.36398998, "returnOnEquity": -0.78492, "freeCashflow": -186334368, "operatingCashflow": -317820992, "revenueGrowth": 1.476, "operatingMargins": -3.77095, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]